CA3164800A1 - Compound for inhibiting neovascularization factors and use thereof - Google Patents

Compound for inhibiting neovascularization factors and use thereof

Info

Publication number
CA3164800A1
CA3164800A1 CA3164800A CA3164800A CA3164800A1 CA 3164800 A1 CA3164800 A1 CA 3164800A1 CA 3164800 A CA3164800 A CA 3164800A CA 3164800 A CA3164800 A CA 3164800A CA 3164800 A1 CA3164800 A1 CA 3164800A1
Authority
CA
Canada
Prior art keywords
compound
hydroxy
alkyl
functional group
chemical formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3164800A
Other languages
English (en)
French (fr)
Inventor
Byoung Heon Kang
So-Yeon Kim
Nam Gu YOON
Changwook Lee
Dong Ho Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smartin Bio Inc
UNIST Academy Industry Research Corp
Original Assignee
Smartin Bio Inc
UNIST Academy Industry Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smartin Bio Inc, UNIST Academy Industry Research Corp filed Critical Smartin Bio Inc
Publication of CA3164800A1 publication Critical patent/CA3164800A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3164800A 2019-12-16 2020-12-16 Compound for inhibiting neovascularization factors and use thereof Pending CA3164800A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0168238 2019-12-16
KR20190168238 2019-12-16
PCT/KR2020/018475 WO2021125800A1 (ko) 2019-12-16 2020-12-16 신생혈관형성인자의 억제를 위한 화합물 및 그 용도

Publications (1)

Publication Number Publication Date
CA3164800A1 true CA3164800A1 (en) 2021-06-24

Family

ID=76477859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3164800A Pending CA3164800A1 (en) 2019-12-16 2020-12-16 Compound for inhibiting neovascularization factors and use thereof

Country Status (9)

Country Link
US (1) US12545695B2 (https=)
EP (1) EP4079309A4 (https=)
JP (1) JP7831775B2 (https=)
KR (1) KR20210076875A (https=)
CN (1) CN114901290B (https=)
AU (1) AU2020409912A1 (https=)
BR (1) BR112022011147A2 (https=)
CA (1) CA3164800A1 (https=)
WO (1) WO2021125800A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901290B (zh) 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途
JP7766885B2 (ja) * 2021-06-15 2025-11-11 スマーティン バイオ インコーポレイテッド Ｔｒａｐ１阻害剤およびその用途
KR102894216B1 (ko) * 2022-12-15 2025-12-18 울산과학기술원 Trap-1 억제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20060229278A1 (en) 1998-11-25 2006-10-12 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
JP4648319B2 (ja) 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
KR20070030815A (ko) 2004-07-13 2007-03-16 오리디스 비오메드 포르슝스-운트 엔트비크룽스 게엠베하 간질환 및 상피암의 치료에서 미토콘드리아적으로 표적화된산화방지제의 용도
US7750018B2 (en) 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
BRPI1014978A2 (pt) 2009-04-17 2019-07-02 Colby Pharmaceutical Company método de tratamento do câncer e composição farmacêutica.
KR101621418B1 (ko) 2014-03-19 2016-05-23 울산과학기술원 미토콘드리아 표적화된 항-종양 조성물
CN114901290B (zh) 2019-12-16 2024-09-03 蔚山科学技术院 抑制血管新生因子的化合物及其用途

Also Published As

Publication number Publication date
WO2021125800A1 (ko) 2021-06-24
AU2020409912A1 (en) 2022-06-16
JP7831775B2 (ja) 2026-03-17
EP4079309A1 (en) 2022-10-26
CN114901290A (zh) 2022-08-12
US12545695B2 (en) 2026-02-10
KR20210076875A (ko) 2021-06-24
US20230088747A1 (en) 2023-03-23
EP4079309A4 (en) 2024-01-10
JP2023506838A (ja) 2023-02-20
CN114901290B (zh) 2024-09-03
BR112022011147A2 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
JP6994538B2 (ja) 医薬化合物
CA3030377C (en) Nitrogen-containing tricyclic compounds and uses thereof in medicine
US7407967B2 (en) Cyclopamine analogues and methods of use thereof
US12545695B2 (en) Compounds for inhibiting neovascularization factors and use thereof
US20060189682A1 (en) Water soluble prodrugs of COX-2 inhibitors
WO2016071283A1 (en) Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
US11382908B2 (en) Compositions and methods for treating inflammatory bowel disease
UA124001C2 (uk) Інгібітори протеїнкіназ, спосіб їх отримання і медичне застосування
CA2700824A1 (en) Heterocyclic compounds as crth2 receptor antagonists
JP2020527139A (ja) Ｎｌｒｐ３モジュレーター
TW202438069A (zh) 依喜替康衍生物及其抗體藥物偶聯物
CN119708105A (zh) 甾体化合物及其应用
EP3765460A1 (en) Inhibition of bmp signaling, compounds, compositions and uses thereof
JP7696301B2 (ja) タンパク質分解のための化合物、組成物、および方法
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
JP7834361B2 (ja) 置換４－（［１，２，４］トリアゾロ［１，５－ａ］ピリジン－６－イル）チオフェン－２－カルボキサミド誘導体及びその使用
CN117769559A (zh) Trap1抑制剂及其用途
CN105582012A (zh) 3’-羟基伊曲康唑的用途
WO2014158302A1 (en) Novel sphingosine 1-phosphate receptor antagonists
JP7766885B2 (ja) Ｔｒａｐ１阻害剤およびその用途
KR102701383B1 (ko) 리포-하이드록삼산 유도체 및 이의 약학적 용도
EP3124024A1 (en) Medicinal composition inhibiting neovascularization proliferation factor
KR20190042960A (ko) 미토콘드리아에 표적화되는 수용성 화합물, 이를 포함하는 조성물 및 이의 제조방법
KR20220167944A (ko) Trap-1 억제제의 안과질환 치료 용도

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20240916

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250825

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129